Please provide your email address to receive an email when new articles are posted on . Postdischarge pharmacotherapy rates rose from 12.6% in 2014 to 23.9% in 2023 for ALD-related hospitalizations.

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...

The stages of behavior change in smoking cessation start with precontemplation, progressing to contemplation, preparation, action, and finally, maintenance.

SEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and ...

Despite decades of progress in reducing the prevalence of cigarette smoking, tobacco use remains a leading cause of preventable death and disease, and a significant driver of health care costs in the ...

Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, ...

Bethesda, MD -Persuading patients with left ventricular dysfunction (LVD) to eschew tobacco will benefit them just as much as treating them with medication, a Canadian study led by Dr Neville Suskin ...

Please provide your email address to receive an email when new articles are posted on . There is a current lack of new, approved smoking cessation therapies. The RespiRx Nicotine Inhaler may address ...

The National Cancer Institute (NCI) has awarded Chrono Therapeutics a Small Business Innovation Research (SBIR) grant of up to $2.3 million for product development of the digital portion of the ...